Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has earned an average rating of "Moderate Buy" from the eight research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $20.00.

Several brokerages recently weighed in on ALT. UBS Group initiated coverage on shares of Altimmune in a report on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a research note on Thursday, November 14th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. raised its stake in shares of Altimmune by 12.9% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company's stock worth $144,000 after buying an additional 2,687 shares during the period. Virtu Financial LLC purchased a new stake in Altimmune in the 3rd quarter worth $674,000. Barclays PLC raised its position in Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company's stock worth $956,000 after acquiring an additional 75,064 shares during the period. Geode Capital Management LLC lifted its holdings in Altimmune by 4.7% during the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company's stock valued at $10,244,000 after purchasing an additional 74,194 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Altimmune by 27.5% in the third quarter. Wellington Management Group LLP now owns 197,232 shares of the company's stock valued at $1,211,000 after purchasing an additional 42,553 shares during the period. Hedge funds and other institutional investors own 78.05% of the company's stock.

Altimmune Trading Up 0.8 %

Shares of NASDAQ:ALT traded up $0.06 on Tuesday, hitting $7.31. 2,179,436 shares of the company were exchanged, compared to its average volume of 2,523,595. The firm has a market capitalization of $519.92 million, a P/E ratio of -4.72 and a beta of 0.22. Altimmune has a 1-year low of $5.28 and a 1-year high of $14.84. The stock's 50 day moving average price is $8.07 and its 200 day moving average price is $7.20.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the firm posted ($0.39) EPS. On average, equities analysts predict that Altimmune will post -1.36 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.